199 related articles for article (PubMed ID: 35544699)
21. Improving Theranostic Gallium-68/Lutetium-177-Labeled PSMA Inhibitors with an Albumin Binder for Prostate Cancer.
Lee BS; Kim MH; Chu SY; Jung WJ; Jeong HJ; Lee K; Kim HS; Kim MH; Kil HS; Han SJ; Lee YJ; Lee KC; Lim SM; Chi DY
Mol Cancer Ther; 2021 Dec; 20(12):2410-2419. PubMed ID: 34725194
[TBL] [Abstract][Full Text] [Related]
22. Synthesis and Evaluation of
Zhao R; Ploessl K; Zha Z; Choi S; Alexoff D; Zhu L; Kung HF
Mol Pharm; 2020 Dec; 17(12):4589-4602. PubMed ID: 33108189
[TBL] [Abstract][Full Text] [Related]
23. Preclinical Dosimetry, Imaging, and Targeted Radionuclide Therapy Studies of Lu-177-Labeled Albumin-Binding, PSMA-Targeted CTT1403.
Ling X; Latoche JD; Choy CJ; Kurland BF; Laymon CM; Wu Y; Salamacha N; Shen D; Geruntho JJ; Rigatti LH; Windish HP; Langton-Webster B; Berkman CE; Anderson CJ
Mol Imaging Biol; 2020 Apr; 22(2):274-284. PubMed ID: 31321650
[TBL] [Abstract][Full Text] [Related]
24. An Improved
Mease RC; Kang CM; Kumar V; Banerjee SR; Minn I; Brummet M; Gabrielson KL; Feng Y; Park A; Kiess AP; Sgouros G; Vaidyanathan G; Zalutsky MR; Pomper MG
J Nucl Med; 2022 Feb; 63(2):259-267. PubMed ID: 34088772
[TBL] [Abstract][Full Text] [Related]
25. Development of
Carpanese D; Ferro-Flores G; Ocampo-Garcia B; Santos-Cuevas C; Salvarese N; Figini M; Fracasso G; De Nardo L; Bolzati C; Rosato A; Meléndez-Alafort L
Sci Rep; 2020 Jun; 10(1):9313. PubMed ID: 32518372
[TBL] [Abstract][Full Text] [Related]
26.
Kristiansson A; Örbom A; Ahlstedt J; Karlsson H; Zedan W; Gram M; Åkerström B; Strand SE; Altai M; Strand J; Vilhelmsson Timmermand O
Biomolecules; 2021 Feb; 11(2):. PubMed ID: 33579037
[TBL] [Abstract][Full Text] [Related]
27. Therapeutic Multidose Preparation of a Ready-to-Use
Chakraborty A; Mitra A; Tawate M; Sahoo S; Lad S; Rakshit S; Gaikwad S; Basu S; Shimpi H; Banerjee S
Cancer Biother Radiopharm; 2021 Oct; 36(8):682-692. PubMed ID: 34402687
[No Abstract] [Full Text] [Related]
28.
Banerjee SR; Kumar V; Lisok A; Chen J; Minn I; Brummet M; Boinapally S; Cole M; Ngen E; Wharram B; Brayton C; Hobbs RF; Pomper MG
Eur J Nucl Med Mol Imaging; 2019 Nov; 46(12):2545-2557. PubMed ID: 31399803
[TBL] [Abstract][Full Text] [Related]
29. Lys-urea-Aad, Lys-urea-Cmc and Lys-urea-Cms as potential pharmacophores for the design of PSMA-targeted radioligands to reduce off-target uptake in kidneys and salivary glands.
Kuo HT; Zhang Z; Zhang C; Merkens H; Tan R; Wong AAWL; Uribe CF; Bénard F; Lin KS
Theranostics; 2023; 13(13):4559-4573. PubMed ID: 37649602
[TBL] [Abstract][Full Text] [Related]
30. [
Lu Q; Long Y; Gai Y; Liu Q; Jiang D; Lan X
Eur J Nucl Med Mol Imaging; 2023 Jul; 50(8):2342-2352. PubMed ID: 36877233
[TBL] [Abstract][Full Text] [Related]
31.
Choy CJ; Ling X; Geruntho JJ; Beyer SK; Latoche JD; Langton-Webster B; Anderson CJ; Berkman CE
Theranostics; 2017; 7(7):1928-1939. PubMed ID: 28638478
[TBL] [Abstract][Full Text] [Related]
32. Radiolabeling of PSMA-617 with
Imura R; Ozeki AN; Shida N; Kobayashi M; Ida H; Wada Y; Akimitsu N; Kumakura Y
Nucl Med Biol; 2022; 106-107():21-28. PubMed ID: 34998216
[TBL] [Abstract][Full Text] [Related]
33. Design and Evaluation of Novel Albumin-Binding Folate Radioconjugates: Systematic Approach of Varying the Linker Entities.
Benešová M; Guzik P; Deberle LM; Busslinger SD; Landolt T; Schibli R; Müller C
Mol Pharm; 2022 Mar; 19(3):963-973. PubMed ID: 35192367
[TBL] [Abstract][Full Text] [Related]
34. New PSMA-Targeting Ligands: Transformation from Diagnosis (Ga-68) to Radionuclide Therapy (Lu-177).
Zha Z; Choi SR; Li L; Zhao R; Ploessl K; Yao X; Alexoff D; Zhu L; Kung HF
J Med Chem; 2022 Oct; 65(19):13001-13012. PubMed ID: 36103652
[TBL] [Abstract][Full Text] [Related]
35.
Privé BM; Derks YHW; Rosar F; Franssen GM; Peters SMB; Khreish F; Bartholomä M; Maus S; Gotthardt M; Laverman P; Konijnenberg MW; Ezziddin S; Nagarajah J; Heskamp S
Eur J Nucl Med Mol Imaging; 2022 May; 49(6):2064-2076. PubMed ID: 34932154
[TBL] [Abstract][Full Text] [Related]
36. Biodistribution and dosimetry of a single dose of albumin-binding ligand [
Kramer V; Fernández R; Lehnert W; Jiménez-Franco LD; Soza-Ried C; Eppard E; Ceballos M; Meckel M; Benešová M; Umbricht CA; Kluge A; Schibli R; Zhernosekov K; Amaral H; Müller C
Eur J Nucl Med Mol Imaging; 2021 Mar; 48(3):893-903. PubMed ID: 32949253
[TBL] [Abstract][Full Text] [Related]
37. Combined Application of Albumin-Binding [
Borgna F; Deberle LM; Cohrs S; Schibli R; Müller C
Mol Pharm; 2020 Jun; 17(6):2044-2053. PubMed ID: 32383887
[TBL] [Abstract][Full Text] [Related]
38. Development of
Potemkin R; Strauch B; Kuwert T; Prante O; Maschauer S
Mol Pharm; 2020 Mar; 17(3):933-943. PubMed ID: 32011889
[TBL] [Abstract][Full Text] [Related]
39. Design and Preclinical Evaluation of a Novel Prostate-Specific Membrane Antigen Radioligand Modified with a Transthyretin Binder.
Vaccarin C; Mapanao AK; Deberle LM; Becker AE; Borgna F; Marzaro G; Schibli R; Müller C
Cancers (Basel); 2024 Mar; 16(7):. PubMed ID: 38610940
[TBL] [Abstract][Full Text] [Related]
40. Synthesis and Preclinical Characterization of the PSMA-Targeted Hybrid Tracer PSMA-I&F for Nuclear and Fluorescence Imaging of Prostate Cancer.
Schottelius M; Wurzer A; Wissmiller K; Beck R; Koch M; Gorpas D; Notni J; Buckle T; van Oosterom MN; Steiger K; Ntziachristos V; Schwaiger M; van Leeuwen FWB; Wester HJ
J Nucl Med; 2019 Jan; 60(1):71-78. PubMed ID: 30237214
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]